載入中
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
收盤時
US$26.40
−US$0.86 · -3.15%
盤後
US$26.40
US$0.00 · 0.00%
10月12日 下午4:39 ET
盤中時間採用ET。市場資料可能有所延遲。
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
日內區間
目前US$26.40
52週區間
目前US$26.40
盤中時間採用ET。市場資料可能有所延遲。
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
日內區間
目前US$26.40
52週區間
目前US$26.40
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 營收 | 1000萬 USD | 500萬 USD | 5000萬 USD | — |
| 銷貨成本 | — | 1.39億 USD | — | 6168.9萬 USD |
| 毛利 | 1000萬 USD | −1.34億 USD | 5000萬 USD | −6168.9萬 USD |
| 研究與開發 | 1.68億 USD | 1.39億 USD | 6003.3萬 USD | 6268.9萬 USD |
| 銷售、一般及管理費用 | 5332.2萬 USD | 2974.9萬 USD | 1711.4萬 USD | 1351萬 USD |
| 營業費用 | 2.21億 USD | 2974.9萬 USD | 8714.7萬 USD | 1451萬 USD |
| 利息收入 | 1215.1萬 USD | — | — | — |
| 利息支出 | 732.7萬 USD | — | — | — |
| 折舊和攤銷 | 5.6萬 USD | 13.7萬 USD | 11.3萬 USD | 7.8萬 USD |
| 營業利益 | −2.11億 USD | −1.64億 USD | −3714.7萬 USD | −7619.9萬 USD |
| 淨利 | −3.78億 USD | −1.57億 USD | −3712.4萬 USD | −1.19億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$43.50
上漲空間 64.77%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2880.35萬0.00%2.3兆 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI2784.93萬0.28%98.74億 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM2561.11萬0.03%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1422.43萬0.01%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO904.83萬0.07%139.17億 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB722.72萬0.07%108.2億 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA658.57萬0.03%218.24億 USD0.03%US$32.66-0.40%
Vanguard Russell 2000 ETFVTWO529.14萬0.03%180億 USD0.06%US$112.27-0.35%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
